FDA to Revamp Rare Disease Efforts

The US government agency vows to improve the way it facilitates the development and approval of drugs for orphan diseases.

Bob Grant
Bob Grant

Bob Grant is Editor in Chief of The Scientist, where he started in 2007 as a Staff Writer.

View full profile.

Learn about our editorial policies.

Sep 12, 2011

WIKIMEDIA, TOM VARCOWith growing interest from the pharmaceutical and biotech industries in addressing diseases that afflict fewer than 200,000 Americans, the US Food and Drug Administration is going to ramp up its efforts to help drug makers develop treatments for rare diseases, the agency announced in a draft, five-year plan released last week. Starting late next year, the FDA's Center for Drug Evaluation and Research will bolster its Rare Disease Program (RDP) by providing pharmaceutical and biotech companies specialized training on the development of drugs for rare, or orphan, diseases and improving its outreach to rare disease patient organizations. According to the draft plan, the agency will also add five new positions to the staff of the RDP, retool the way it evaluates the success of the program, and hold public meetings to hear concerns and suggestions from stakeholders in rare disease drug development. On October 14th of this...

Interested in reading more?

FDA to Revamp Rare Disease Efforts

The Scientist ARCHIVES

Become a Member of

Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member?